
## Seung-Keun Hong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10002218/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Analogs of the Heat Shock Protein 70 Inhibitor MKT-077 Suppress Medullary Thyroid Carcinoma Cells. International Journal of Molecular Sciences, 2022, 23, 1063.	4.1	9
2	Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-RafV600E melanoma cells. Cancer Letters, 2021, 502, 25-33.	7.2	11
3	Mortalin (HSPA9) facilitates <i>BRAF</i> -mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability. Science Signaling, 2020, 13, .	3.6	24
4	Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability. Oncogene, 2020, 39, 4257-4270.	5.9	22
5	Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells. International Journal of Molecular Sciences, 2019, 20, 2069.	4.1	40
6	A cellular threshold for active ERK1/2 levels determines Raf/MEK/ERK-mediated growth arrest versus death responses. Cellular Signalling, 2018, 42, 11-20.	3.6	22
7	Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells. Cancer Biology and Therapy, 2017, 18, 473-483.	3.4	17
8	Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in <i>KRAS</i> and <i>BRAF</i> Tumor Cells. Molecular and Cellular Biology, 2017, 37, .	2.3	20
9	Suppression of B-Raf <sup>V600E</sup> melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone. Cancer Biology and Therapy, 2017, 18, 106-114.	3.4	20
10	ERK1/2 can feedback-regulate cellular MEK1/2 levels. Cellular Signalling, 2015, 27, 1939-1948.	3.6	21
11	Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines. Genes and Genomics, 2014, 36, 829-841.	1.4	15
12	Raf/MEK/ERK can regulate cellular levels of LC3B and SQSTM1/p62 at expression levels. Experimental Cell Research, 2014, 327, 340-352.	2.6	90
13	AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion. Experimental Cell Research, 2013, 319, 1732-1743.	2.6	20
14	Autophagy sensitivity of neuroendocrine lung tumor cells. International Journal of Oncology, 2013, 43, 2031-2038.	3.3	15
15	The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells. Experimental Cell Research, 2011, 317, 2671-2682.	2.6	41
16	Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Cancer Letters, 2010, 297, 31-41.	7.2	43
17	Noncatalytic Function of ERK1/2 Can Promote Raf/MEK/ERK-mediated Growth Arrest Signaling. Journal of Biological Chemistry, 2009, 284, 33006-33018.	3.4	73
18	Fluorescein Clearance Kinetics in Blood and Bile Indicates Hepatic Ischemia-Reperfusion Injury in Rats. American Journal of Physiology - Renal Physiology, 0, , .	3.4	1